Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Amivantamab + Lazertinib for Lung Cancer
Recruiting1 awardPhase 2
Montvale, New Jersey
This trial is testing two drugs, amivantamab and lazertinib, to see if they are effective against metastatic NSCLC with an EGFR mutation. Both drugs work by targeting cancer cells with an EGFR mutation.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service